Own the Gate.

Someone or something has to decide if a medicine is appropriate and safe for use. For seventy-five years that was a prescription pad. It is becoming software. An ACNU puts that software on your site, validated by FDA, and keeps the sale there.

The house has three parts

the door: Where the person walks in; today: yours
the gate: Where it is decided safe; today: not yours
the counter: Where the sale closes; today: not yours

Own the Gate, and the counter follows.

01 · the handoff

We already pay for the visit. Then we hand it off.

Pharma spends about six billion dollars a year on TV to bring a patient to a brand site. The site cannot sell. It says: talk to your doctor. From there the office, the PBM and the counter own the outcome.

Of every hundred prescriptions written, twenty-eight are never picked up and thirty-six more stop within a year. Thirty-six patients remain.

Hand it off, and someone else owns the gate and the counter.

Fig. 01a · today’s Rx funnel

Paid media$6B · yours

Brand.comyours · no sale

“Talk to your doctor”the handoff

Office · PBM · counternot yours

SourceeMarketer, iSpot.tv data, Jan 2026: national TV Rx drug ad spend 2025, $5.96B

Of every 100 prescriptions written

never picked up: 28
stopped within a year: 36
still taking it at 12 months: 36

SourcesAMN Healthcare 2025 wait-time survey (31 days) · Fischer et al., J Gen Intern Med 2010 (28% never filled) · Vrijens et al., BMJ 2008 (about half stop within a year)

02 · first principles

Two jobs are irreducible.
Both are moving.

Strip drug access to the studs and two jobs remain: someone must pay, and something must decide it is safe. Everything else is scaffolding. Both are changing hands at once.

Fig. 02a · drug access, to the studs

the patient

someone must pay · the financierEighty years of employer and government insurance

→ moving to the consumer’s card

+58%

average out-of-pocket marketplace premium increase, 2026

37M

Americans uninsured by 2036, from 30M this year

something must decide it’s safe · the gateSeventy-five years of a licensed human with a prescription pad

→ moving to software

1 in 3

U.S. adults asked an AI for health advice in the past year

190

chronic medications an AI renews without a clinician in Utah’s sandbox

the medicine

scaffolding

office visitsprior authPBMsformulariescopay cardsrefill appointments

SourcesKFF, 2026 ACA Marketplace Enrollment, Premiums, and Deductibles, May 2026 ($113 to $178 a month) · CBO, Federal Subsidies for Health Insurance 2026 to 2036, Jul 2026 · KFF Tracking Poll on Health Information and Trust, Mar 2026 (32%) · Utah Dept. of Commerce and Doctronic, Jan 2026

Routine medicine will be consumer-funded and software-gated.Both shifts are already underway. The question is whose software ends up at the gate, and who validated it.

03 · the gate with a pathway

One gate. Every front door.

An Additional Condition for Nonprescription Use, an ACNU, is an FDA-approved questionnaire a consumer answers to buy a medicine without a prescription. It lives in the NDA, so it can’t drift. The front door is moving: 300 million people a week ask ChatGPT about their health, but the purchase still happens on the brand’s site. The agent layer carries the same questionnaire to every front door and sends qualified consumers to your counter.

Fig. 03a · six front doors, one gate, two outcomes

front doors · today

Brand.comRetail shelf & kioskRetailer app

front doors · arriving

AI health serviceShopping assistantThe consumer’s own agent

the agent layer

01meets you at any door
02helps you answer
03passes your answers on
04logs every step

the questionnaireThe approved conditionvalidated · locked · makes every call

qualifiesBuy or subscribe on your site

screened outReferred to a clinician

SourcesOpenAI, Launching Health in ChatGPT, Jul 2026 (300M+ weekly, up from 230M in Jan) · Daniel Danker, Walmart, WIRED Mar 2026 and CNBC Mar 2026 (conversion on retailer site vs in-chat checkout) · Amazon Q4 2025 earnings, Feb 2026 ($12B via Rufus)

Fig. 03b · the pathway, 2012 to next

2012 · NSURE
“Safe use” conditions beyond the label.
2022 · proposed rule
The ACNU named.
Dec 2024 · final rule
Web, app or kiosk. Separate NDA. In effect May 2025.
Nov 2026 · OMUFA II §6507
FDA switch plan due. Guidance by May 2027.
next · the agent layer
The questionnaire, carried to every front door. Submitted with it.

SourcesFDA NSURE public hearing, Mar 2012 · Proposed rule, 87 FR 38313, Jun 2022 · Final rule, 89 FR 105288, Dec 2024, effective May 27 2025 · 21 CFR 314.56 · Pub. L. 119-37 §6507 (OMUFA II), signed Nov 12 2025 Rule details in the ACNU FAQ.

Somebody’s software has to be validated. The ACNU does it inside the NDA. It is yours.

04 · door · gate · counter

We build all three.

An ACNU program is a feasibility question, a validated piece of software and a storefront. The leaderboard answers the first for every brand. TACTiC proved the second in an actual-use study.

the door

phase 1

ACNU Feasibility

Is this molecule a switch candidate, and is there a consumer at the door?

Unmet need and self-selection risk
Safety profile against the ACNU scorecard
Market size and the LOE clock
A public grade on the ACNU leaderboard

See graded brands →

the gate

phase 2

Build & Study

The questionnaire as software, validated as a device, proven in an actual-use study.

Self-selection technology, web, app and kiosk
SaMD validation and cybersecurity
Agent-layer delivery of the same questionnaire
Trial recruitment and study support

the counter

phase 3

Commercialization

The sale closes where the gate is. Your site, by subscription, through the cliff.

Checkout, subscription and fulfillment
Reporting and optimization
Marketing and AI visibility
No PBM, no formulary, no counter substitution

Expedite Time-to-Market

Weeks from a go decision

Pre-studies: 6 wks; Label comprehension and self-selection studies on the built technology.
Validation studies: 8 wks; SaMD validation and cybersecurity, ready for review.
Actual use study: 12 wks; From go decision to an actual use study on our ACNU platform.

05 · proof

The gate has already been built once.

The pathway is young. The work is not hypothetical.

Fig. 05a · TACTiC trial, ACC 2024

A technology-assisted self-selection study for a nonprescription statin.

AstraZeneca’s TACTiC trial tested whether consumers could use a web questionnaire to self-select for, and appropriately use, rosuvastatin calcium 5-mg over six months. We built and ran the technology. Results were presented at ACC in April 2024.

Fig. 05b · the feasibility grade

Every brand graded, in public.

Every brand on the ACNU leaderboard carries a feasibility grade built from an eight-part scorecard: side-effect severity, therapeutic window, dependency risk, interactions, special populations, dosing complexity, monitoring and adherence. How the grade is built.

the grade scale · A+ to F

Measurable change

Six months, no practitioner

Self-selection: 91.7%
Actual use: 98.1%
Adherence: 95.0%
LDL reduction: −35.5%

SourceTACTiC, American College of Cardiology 2024

06 · the clock

Leave the counter before the cliff.

On day one of generic entry the counter swaps the brand out. A year later it holds about a fifth of its units. A nonprescription launch at LOE minus one takes the shelf first and turns refills into subscriptions the counter cannot substitute. Feasibility to launch is about four years. Three clocks are running. The sponsor sets none of them.

consumersNow

300M+ a week already ask an AI. The door has moved.

FDANov 2026

Switch plan due under OMUFA II. Guidance follows by May 2027.

your cliffLOE −5

Four years to LOE −1. For a 2031 cliff, start now.

SourcesGrabowski et al., J Med Econ 2021: brands retain about 18 to 23% of units a year after generic entry · FDA, Generic Competition and Drug Prices, Dec 2019 The revenue curve is drawn on Drug Patent Cliff Strategies.

Fig. 06b · cliff audit · type your LOE year

When does your brand lose exclusivity?

LOE year · type a year or step it

Change the year and the three dates update.

start feasibility2027LOE −5

OTC on shelf2031LOE −1

generic entry2032the cliff

Generic entry in 2032. Start feasibility in 2027 and the nonprescription launch lands in 2031.

See graded brands on the ACNU leaderboard →

Who owns the gate? Whoever's software FDA validated. Make sure it's yours.

Connect With Us

Own the Gate before someone else does.

Whether the opportunity begins with visibility or nonprescription access, we’ll help you find the clearest next move across Search, AI and ACNU.

contact@idea-evolver.com